The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery by Douglas, Alexandra et al.
STUDY PROTOCOL Open Access
The pharmacokinetics of cefazolin in patients
undergoing elective & semi-elective abdominal
aortic aneurysm open repair surgery
Alexandra Douglas
1,2, Mahdi Altukroni
1,2, Andrew A Udy
1,2, Michael S Roberts
3,4, Kersi Taraporewalla
5,
Jason Jenkins
6, Jeffrey Lipman
1,2, Jason A Roberts
1,2,7*
Abstract
Background: Surgical site infections are common, so effective antibiotic concentrations at the sites of infection are
required. Surgery can lead to physiological changes influencing the pharmacokinetics of antibiotics. The aim of the
study is to evaluate contemporary peri-operative prophylactic dosing of cefazolin by determining plasma and
subcutaneous interstitial fluid concentrations in patients undergoing elective of semi-elective abdominal aortic
aneurysm (AAA) open repair surgery.
Methods/Design: This is an observational pharmacokinetic study of patients undergoing AAA open repair surgery
at the Royal Brisbane and Women’s Hospital. All patients will be administered 2-g cefazolin by intravenous injection
within 30-minutes of the procedure. Participants will have samples from blood and urine, collected at different
intervals. Patients will also have a microdialysis catheter inserted into subcutaneous tissue to measure interstitial
fluid penetration by cefazolin. Participants will be administered indocyanine green and sodium bromide as well as
have cardiac output monitoring performed and tetrapolar bioimpedance to determine physiological changes
occurring during surgery. Analysis of samples will be performed using validated liquid chromatography tandem
mass-spectrometry. Pharmacokinetic analysis will be performed using non-linear mixed effects modeling to
determine individual and population pharmacokinetic parameters and the effect of peri-operative physiological
changes on cefazolin disposition.
Discussion: The study will describe cefazolin levels in plasma and the interstitial fluid of tissues during AAA open
repair surgery. The effect of physiological changes to the patient mediated by surgery will also be determined. The
results of this study will guide clinicians and pharmacists to effectively dose cefazolin in order to maximize the
concentration of antibiotics in the tissues which are the most common site of surgical site infections.
Background
Surgical site infections are of significant concern to the
healthcare system and are the second most common
type of adverse-event occurring in hospitalized patients
[1]. Patients undergoing clean-contaminated and clean
surgeries are reported to have infection rates of 11% and
1% respectively [2]. The consequences of such complica-
tions are dependent on the sites of infections as well as
disease severity. Additionally, patients will be exposed
to significant morbidities and mortalities including
bronchopneumonia (8%), renal insufficiency (5%) and
wound infection (3%) as well as myocardial infarction
(3%), stroke (2%) and pulmonary embolism (1%) respec-
tively [3]. They will also suffer the financial burden of a
prolonged hospital stay, thereby also impacting on the
health care system. An attempt to minimise such com-
plications will provide significant cost-effectiveness
advantages for the health care system. Furthermore, the
inappropriate use of antibiotics will impose selective
antibiotic pressure in the hospital environment. Antibio-
tics are considered an essential part of the surgical
prophylaxis strategy. Identifying the pharmacokine-
tic properties of antibiotics and the likely alteration
* Correspondence: j.roberts2@uq.edu.au
1Burns, Trauma and Critical Care Research Centre, School of Medicine, The
University of Queensland, Brisbane, Queensland, Australia
Full list of author information is available at the end of the article
Douglas et al. BMC Anesthesiology 2011, 11:5
http://www.biomedcentral.com/1471-2253/11/5
© 2011 Douglas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.during surgical interventions would facilitate rational
prescription.
Different types of surgeries will have different levels of
effect on pharmacokinetics. For example, burn patients
undergoing excisions and bone grafting can have drama-
tically different antibiotic pharmacokinetic parameters
compared with healthy volunteers. In a previous study
from our group we were able to show that conventional
single peri-operative antibiotic prophylaxis did not
achieve adequate plasma concentrations above estab-
lished minimum inhibitory concentrations (MIC) for
target organisms during lengthy debridement procedures
[4]. Antibiotic concentrations in the interstitial fluid of
tissues are likely to be more informative than plasma
concentrations in this setting, as tissues are far more
likely to be the site of infection [5].
Another common surgical procedure for which little
data is available to describe the interstitial fluid concen-
trations of prophylactic antibiotics is abdominal aortic
aneurysm (AAA) open repair surgery. This type of sur-
gery often results in blood losses in large quantities
requiring the need for volume replacement as well as
vasopressors and inotropic support. Each of these factors
is capable of increasing the clearance of hydrophilic com-
pounds such as the antibiotics typically used for prophy-
laxis in this population [6]. Other confounding factors in
this population include the age of these patients (mostly
65-75 years) and the fact that many patients have compli-
cations of diabetes and hypertension including nephropa-
thy and vasculopathy [3,7]. In addition, these patients are
going to have major blood vessels surgically clamped
temporarily reducing kidney perfusion and potentially
altered perfusion of other tissues. Consequently, tissue
concentrations of antibiotics may be inadequate. In light
of this, it appears that there are many complexities in
achieving adequate tissue concentrations of antibiotics.
The complex interrelationship of altered physiology and
pharmacokinetics has been recently described [6,8].
The relationship between surgical site infections and
the sub-optimal antibiotic concentrations during surgery
has been established for aminoglycosides but not specifi-
cally for beta-lactams [9]. Therefore, obtaining the con-
centrations of antibiotics at the sites of infection will be
beneficial to enhance our understanding of the pharma-
cokinetics of our selected antibiotics. Tissue concentra-
tions of antibiotics are best determined by a technique
known as microdialysis [10,11].
Cefazolin is recommended by the Australian Thera-
peutic Guidelines for prophylaxis in vascular surgery. It
belongs to the cephalosporin class of antibiotics and
provides an excellent coverage against Gram positive
bacteria and limited activity against Gram negatives.
Cephalosporins display time-dependent killing meaning
maximal bacterial killing requires maximal duration of
exposure with the time for which the unbound (or free)
antibiotic concentration is maintained above the MIC (f
T>M I C ) being the index correlated with efficacy. To the
best of our knowledge, there are no studies that describe
tissue concentrations of antibiotics during AAA open
repair surgery. We hypothesise that measurement of
these concentrations will enable procurement of doses
that could optimize the concentrations of antibiotics in
the interstitial space, where infections are likely to
occur.
Aims
To describe the pharmacokinetics of cefazolin adminis-
tered intravenously to patients undergoing elective and
semi-elective AAA open repair surgery: to subsequently
develop a rational physiological population pharmacoki-
netic model that describes plasma and tissue concentra-
tions of cefazolin in these patients.
Methods/Design
This is an observational pharmacokinetic study. Blood,
urine, and microdialysate samples will be collected at
established intervals from participants presenting to the
Royal Brisbane and Women’s Hospital, undergoing elec-
tive or semi-elective AAA open repair surgery.
Setting
The Intensive Care Unit at the Royal Brisbane and
Women’s Hospital is a 30-bed tertiary referral unit with
2000-2500 admissions per year. This study is done in
collaboration with the Burns, Trauma and Critical Care
Research Centre, School of Medicine, the University of
Queensland, as well as the Departments of Anaesthesia
and Vascular Surgery at the Royal Brisbane and Women’s
Hospital.
Identification of eligible patients
Patients undergoing elective and semi-elective AAA open
repair surgery, who fulfil the inclusion and exclusion cri-
teria will be eligible for the study. Written informed con-
sent will be obtained from each participant.
Inclusion Criteria
1. Age > 18 years and < 90 years.
2. Patients scheduled for elective and semi-elective
Abdominal Aortic Aneurysm (AAA) repair.
3. Prescription of intravenous cefazolin for peri-
operative surgical prophylaxis.
4. An arterial line in situ.
5. Informed consent by the patient or a legally
authorized representative to participate in the study
and to store specimens for immediate and future
analysis.
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1. Prior prescription of cefazolin within the preced-
ing 72-hours.
2. Known allergy to the study drug.
3. Patients whose religion or personal beliefs limit
the physician’s ability to conduct standard resuscita-
tion during surgery (e.g. Jehovah’s Witness).
Participants
Participants will be identified by either a Consultant
Anaesthetist or a Vascular Surgeon. All participants will
receive the same dose of cefazolin and will receive the
same protocol.
Drug dosing
All participants will receive cefazolin 2 g (Cephazolin,
DBL, Sydney Australia) in 10 ml 0.9% sodium chloride
as a 3-minute slow bolus intravenous injection within
30-minutes of the first incision of surgery.
Patients will be given marker compounds to determine
any alteration in the patient’s physiology as a result of the
surgery. Indocyanine green (ICG) - Pulsion 0.5 mg/kg
(maximum dose 50 mg) will be administered to provide a
measure of plasma volume, an indication of hepatic func-
tion and the distribution kinetics of highly bound solutes.
Plasma volume will be obtained from the last ICG con-
centration [12]. The ICG will be administered as a rapid
bolus via central venous line 10 min prior to the start of
the antibiotic infusion. ICG non-invasive oximetry mea-
surements will be taken over a period of 7 min.
Sodium bromide (5% w/v solution; 1 ml/kg; Central
Pharmacy, Brisbane, Australia) will be administered
intravenously to measure extracellular and intracellular
fluid fluctuations [13]. It will be administered as a 2.5 g
slow bolus over 3 min. Sodium bromide will be adminis-
tered starting 3 min before administration of cefazolin.
Microdialysis
The principles and details of microdialysis have been
described previously [10]. Briefly, microdialysis is based
on the sampling of analytes from the extracellular space
by diffusion across a semi-permeable membrane. In
vivo, this process is accomplished by constantly perfus-
ing the microdialysis probe with a physiological solution
at a low flow rate. Once the probe is implanted in tis-
sue, analytes diffuse across the membrane from
t h ee x t r a c e l l u l a rf l u i di n t ot h ep e r f u s a t ea n dm a yb e
sampled and analysed. In this study, a microdialysis
probe (CMA 60, Microdialysis AB, Stockholm, Sweden)
with a molecular weight cut off of 20 kD, an outer dia-
meter of 0.6 mm and a membrane length of 30 mm was
aseptically placed in the subcutaneous tissue of the
upper arm of each patient. The probe will be perfused
with cefalotin (10 mg/L; internal standard; Cephalothin,
DBL, Sydney Australia) in 0.9% sodium chloride at a
flow rate of 1.6 μl/min [10]. The recovery of cefazolin in
the microdialysate solution was interpolated from the
loss of internal standard (cefalotin) across the microdia-
lysis membrane into tissue according to the retrodialysis
method [14,15].
% cefazolin recovery = 1     C mean C C in out in 00   –/
Where Cin = cefalotin 2 mg/L (perfusate); Cout = mea-
sured cefalotin concentration in microdialysate
Other measurements performed
Tetrapolar Bioimpedance
An experienced clinician will perform tetrapolar bioim-
pedance on two occasions during the study. The first
measurement will occur 20 minutes prior to the antibio-
tic dose and then repeated at the conclusion of sam-
pling. The results will be used for measuring the fat free
mass [11] of the patient and detecting altered fluid sta-
tus over the study period and to calculate the drug
volume of distribution.
Cardiac Output
Non-invasive pulse contour arterial waveforms will be
taken to measure cardiac output and other derived mea-
surements utilizing the FloTrac/Vigileo™ system
(Edwards Lifesciences, Irvine, CA, USA). Obtained car-
diac output results will be confirmed using an UltraSo-
nic Cardiac Output Monitor (The USCOM ultrasonic
cardiac output monitor USCOM Pty, Coffs Harbour,
NSW, Australia). These measurements will be compared
at three times points (30-minutes prior to antibiotic
administration, 2 hours after antibiotic administration
and then 60-minutes after skin closure).
Sample collection
All participants will have blood sampling at the follow-
ing times, 0 minutes (prior to the dose), 3, 10, 30, 60,
90, 180, 300, and finally at 480 (minutes) following the
dose or until the end of surgery.
Urine will be collected at two-hourly intervals during
pre- and peri-operative periods. A 10 ml aliquot will be
used to determine renal clearance of cefazolin in the
two-hour time interval with the balance of urine used to
calculate 2-hour urinary creatinine clearance. Further to
this, an eight-hourly urinary creatinine clearance will
also be taken post-operatively to determine the partici-
pant’s renal function at the end of the procedure.
Microdialysate samples will be collected at 30-minute
intervals during the pre- and the post-operative periods
to provide a continuous description of interstitial con-
centrations of cefazolin.
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Blood will be centrifuged at 3000 rpm for 10 minutes
before being stored at -80°C until assay.
Sample analysis
Analysis of plasma, urine and microdialysis samples will
be performed by validated liquid chromatography tan-
dem-mass spectrometry (LC-MS/MS) methodology at
t h eT h e r a p e u t i c sR e s e a r c hU n i t ,T h eU n i v e r s i t yo f
Queensland.
Data collection
Additional data will be obtained from the participant or
extraction from the clinical notes. These include:
1. Participant information - age, gender, weight,
height, allergies.
2. Clinical details including the admitting diagnosis,
the progress, and the outcome.
3. Laboratory investigations - full blood count, elec-
trolytes, liver function tests, arterial blood gasses,
and coagulation profile.
4. Details of surgical procedure - aortic clamp timing
and duration, fluid administration requirements.
5. Results of all microbiological studies (performed
as a part of standard practice).
6. Glomerular filtration rate will be estimated from
creatinine clearance but it will be calculated from
serum creatinine and the urine sample collected at
eight-hours post-operatively during the initial study
period.
7. Co-morbidities.
8. Evidence of organ dysfunction.
Statistical considerations
This is a non-interventional study and is not intended to
compare between different treatment modalities and
therefore a power calculation is not possible. The pur-
pose of the study is to identify the significant covariates
that can describe the variability in cefazolin pharmacoki-
netics in participants undergoing AAA repair surgery.
A sample size of twelve is considered sufficient to identify
the most clinically significant covariates in this pharma-
cokinetic study. In general, population pharmacokinetic
studies have fewer statistical design restrictions [16].
Data analysis
The results of the sample analysis will be analysed using
a non-linear mixed effects modelling approach with the
pharmacokinetic computer software program NON-
MEM
® (GlobMax LLC, Hanover, MD, USA) to develop
a model for cefazolin dosing via the intravenous route
when given as a prophylaxis during AAA open repair
surgery. Pharmacokinetic parameters (volume of distri-
bution, clearance, and half lives) will be compared with
a l r e a d yp u b l i s h e dd a t au s i n gt h eM a n n - W h i t n e yt e s t .
The influence of demographics and clinical covariates
will be evaluated as well. The model will simulate cefa-
zolin pharmacokinetics for patients undergoing AAA
open repair surgery to best evaluate the adequacy of a
single dose of 2 g of cefazolin, intravenously given as
surgical prophylaxis.
Ethical considerations
The Human Research and Ethics Committee of the
Royal Brisbane and Women’s Hospital (2007/187) and
the medical Research Ethics committee of The Univer-
sity of Queensland (2008002032) have approved this
study.
Withdrawal from the study
Participants may withdraw from the study at anytime
without prejudice, as documented and explained at the
time of consenting.
Discussion
Surgical site infections can be minimized by optimizing
peri-operative antibiotic prophylaxis doses. The current
study is the first to document plasma and interstitial
fluid levels of cefazolin in patients undergoing AAA
open repair surgery. Further, we are unaware of any
other studies that describe the changing physiology of
the patient during the peri-operative period in the pro-
posed level of detail. We believe that maximizing the
concentration of antibiotics at the likely sites of infec-
tions, namely the interstitial fluid, will help to obviate
the problem of inadequate prophylaxis. Patients under-
going AAA repair surgery are expected to undergo phy-
siological changes related to fluid and vasopressor
administration and aortic clamping likely to affect anti-
biotic volumes of distributions and clearance. In light of
this, these patients may be at risk of inadequate antibio-
tic concentrations in the interstitial fluid of tissues.
In conclusion, our study will describe the likely ade-
quacy of cefazolin when administered intravenously as a
prophylaxis to patients undergoing AAA open repair
surgery by measuring its concentration at tissues using
microdialysis [10,11]. Various peri-operative pathophy-
siological changes will also be measured in an attempt
to understand antibiotic distribution variables.
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